Pure cannabidiol in the treatment of malignant migrating partial seizures in infancy: a case report

Pediatr Neurol. 2015 May;52(5):544-7. doi: 10.1016/j.pediatrneurol.2015.02.008. Epub 2015 Feb 19.


Background: Malignant migrating partial seizures in infancy is a devastating pharmacoresistent epileptic encephalopathy of unknown etiology characterized by onset in the first 6 months of life, continuous migrating focal seizures with corresponding multifocal electroencephalographic discharges, developmental deterioration, and early mortality. Recent widespread interest in the nonpsychoactive component of the cannabis plant, cannabidiol, as a potential treatment for refractory devastating epilepsies has led to individual trials initiated by families or physicians in states that have legalized medical marijuana with anecdotal success.

Patient description: We describe a now 10-month-old boy with malignant migrating partial seizures in infancy who made developmental gains and demonstrated sustained seizure reduction with the addition of cannabidiol to his antiepileptic regimen.

Conclusion: This report supports a role for cannabidiol in the treatment of malignant migrating partial seizures in infancy.

Keywords: CBD; cannabidiol; ketogenic diet; malignant migrating partial epilepsy; migrating partial seizures.

Publication types

  • Case Reports

MeSH terms

  • Anticonvulsants / therapeutic use*
  • Cannabidiol / therapeutic use*
  • Electroencephalography
  • Epilepsies, Partial / drug therapy*
  • Humans
  • Infant
  • Male


  • Anticonvulsants
  • Cannabidiol